López MJ, Carbajal J, Alfaro AL, Saravia LG, Zanabria D, Araujo JM, et al. Characteristics of gastric cancer around the world. Crit Rev Oncol Hematol. 2023;181:103841.

Article  PubMed  Google Scholar 

Smyth EC, Nilsson M, Grabsch HI, van Grieken NCT, Lordick F. Gastric cancer. Lancet. 2020;396:635–48.

Article  CAS  PubMed  Google Scholar 

Li K, Zhang A, Li X, Zhang H, Zhao L. Advances in clinical immunotherapy for gastric cancer. Biochim Biophys Acta Rev Cancer. 2021;1876:188615.

Article  CAS  PubMed  Google Scholar 

Patel TH, Cecchini MA-O. Targeted therapies in advanced gastric cancer. Curr Treat Options Oncol. 2020;21:70.

Article  PubMed  Google Scholar 

Liu Y, Han X, Li L, Zhang Y, Huang X, Li G, et al. Role of Nectin–4 protein in cancer (review). Int J Oncol. 2021;59:93.

Article  CAS  PubMed  Google Scholar 

Delpeut S, Sisson G, Black KM, Richardson CD. Measles Virus enters breast and Colon cancer cell lines through a PVRL4-Mediated macropinocytosis pathway. J Virol. 2017;91:e02191–02116.

Article  PubMed  PubMed Central  Google Scholar 

Bouleftour W, Guillot A, Magne N. The anti-nectin 4: a promising Tumor cells target. A systematic review. Mol Cancer Ther. 2022;21:493–501.

Article  CAS  PubMed  Google Scholar 

Chatterjee S, Sinha S, Kundu CN. Nectin cell adhesion molecule-4 (NECTIN-4): a potential target for cancer therapy. Eur J Pharmacol. 2021;911:174516.

Article  CAS  PubMed  Google Scholar 

Powles T, Rosenberg JE, Sonpavde GP, Loriot Y, Duran I, Lee JL, et al. Enfortumab Vedotin in previously treated advanced Urothelial Carcinoma. N Engl J Med. 2021;384:1125–35.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhou W, Fang P, Yu D, Ren H, You M, Yin L, et al. Preclinical evaluation of 9MW2821, a site-specific Monomethyl Auristatin E-based antibody-drug conjugate for treatment of Nectin-4-expressing cancers. Mol Cancer Ther. 2023;22:913–25.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rigby M, Bennett G, Chen L, Mudd GE, Harrison H, Beswick PJ, et al. BT8009; a Nectin-4 targeting bicycle toxin conjugate for treatment of solid tumors. Mol Cancer Ther. 2022;21:1747–56.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Porebska N, Ciura K, Chorazewska A, Zakrzewska M, Otlewski J, Opalinski L. Multivalent protein-drug conjugates - an emerging strategy for the upgraded precision and efficiency of drug delivery to cancer cells. Biotechnol Adv. 2023;67:108213.

Article  CAS  PubMed  Google Scholar 

Cox NA-O, Kintzing JR, Smith M, Grant GA, Cochran JA-O. Integrin-targeting knottin peptide-drug conjugates are potent inhibitors of tumor cell proliferation. Angew Chem Int Ed Engl. 2016;55:9894–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Currier NV, Ackerman SE, Kintzing JR, Chen R, Filsinger Interrante M, Steiner A, et al. Targeted drug delivery with an integrin-binding Knottin-Fc-MMAF Conjugate Produced by cell-free protein synthesis. Mol Cancer Ther. 2016;15:1291–300.

Article  CAS  PubMed  Google Scholar 

Brandl F, Busslinger S, Zangemeister-Wittke U, Pluckthun A. Optimizing the anti-tumor efficacy of protein-drug conjugates by engineering the molecular size and half-life. J Control Release. 2020;327:186–97.

Article  CAS  PubMed  Google Scholar 

Wu Y, Li Q, Kong Y, Wang Z, Lei C, Li J, et al. A highly stable human single-domain antibody-drug conjugate exhibits superior penetration and treatment of solid tumors. Mol Ther. 2022;30:2785–99.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen P, Bordeau BM, Zhang Y, Balthasar JP. Transient inhibition of Trastuzumab-Tumor binding to overcome the binding-site barrier and improve the efficacy of a Trastuzumab-Gelonin Immunotoxin. Mol Cancer Ther. 2022;21:1573–82.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Thurber GM, Schmidt MM, Wittrup KD. Factors determining antibody distribution in tumors. Trends Pharmacol Sci. 2008;29:57–61.

CAS  PubMed  PubMed Central  Google Scholar 

Cilliers C, Guo H, Liao J, Christodolu N, Thurber GM. Multiscale modeling of antibody-drug conjugates: connecting tissue and cellular distribution to whole animal pharmacokinetics and potential implications for efficacy. AAPS J. 2016;18:1117–30.

Article  CAS  PubMed  Google Scholar 

Debie P, Lafont C, Defrise M, Hansen I, van Willigen DM, van Leeuwen FWB, et al. Size and affinity kinetics of nanobodies influence targeting and penetration of solid tumours. J Control Release. 2020;317:34–42.

Article  CAS  PubMed  Google Scholar 

Xenaki KT, Dorrestijn B, Muns JA, Adamzek K, Doulkeridou S, Houthoff H, et al. Homogeneous tumor targeting with a single dose of HER2-targeted albumin-binding domain-fused nanobody-drug conjugates results in long-lasting tumor remission in mice. Theranostics. 2021;11:5525–38.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jovcevska I, Muyldermans S. The therapeutic potential of nanobodies. BioDrugs. 2020;34:11–26.

Article  CAS  PubMed  Google Scholar 

Ackaert C, Smiejkowska N, Xavier C, Sterckx YGJ, Denies S, Stijlemans B, et al. Immunogenicity risk profile of nanobodies. Front Immunol. 2021;12:632687.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Scully M, Cataland SR, Peyvandi F, Coppo P, Knöbl P, Kremer Hovinga JA, et al. Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura. N Engl J Med. 2019;380:335–46.

Article  CAS  PubMed  Google Scholar 

Safarzadeh Kozani P, Naseri A, Mirarefin SMJ, Salem F, Nikbakht M, Evazi Bakhshi S, et al. Nanobody-based CAR-T cells for cancer immunotherapy. Biomark Res. 2022;10:24.

Article  PubMed  PubMed Central  Google Scholar 

Berdeja JG, Madduri D, Usmani SZ, Jakubowiak A, Agha M, Cohen AD, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet. 2021;398:314–24.

Article  CAS  PubMed  Google Scholar 

Martin T, Usmani SZ, Berdeja JG, Agha M, Cohen AD, Hari P, et al. Ciltacabtagene Autoleucel, an Anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed/refractory multiple myeloma: CARTITUDE-1 2-Year Follow-Up. J Clin Oncol. 2023;41:1265–74.

Article  CAS  PubMed  Google Scholar 

Ma J, Xu X, Fu C, Xia P, Tian M, Zheng L, et al. CDH17 nanobodies facilitate rapid imaging of gastric cancer and efficient delivery of immunotoxin. Biomater Res. 2022;26:64.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nambulli SA-O, Xiang YA-O, Tilston-Lunel NA-O, Rennick LA-O, Sang ZA-O, Klimstra WB, et al. Inhalable nanobody (PiN-21) prevents and treats SARS-CoV-2 infections in Syrian hamsters at ultra-low doses. LID – 10.1126/sciadv.abh0319 [doi] LID - eabh0319. Sci Adv. 2021;7:eabh0319.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hmila I, Cosyns B, Fau - Tounsi H, Tounsi H, Fau - Roosens B, Roosens B, Fau - Caveliers V, Caveliers V, Fau - Abderrazek RB et al. Abderrazek Rb Fau - Boubaker S,. Pre-clinical studies of toxin-specific nanobodies: evidence of in vivo efficacy to prevent fatal disturbances provoked by scorpion envenoming. Toxicol Appl Pharmacol. 2012, 264:222–231.

Steeland S, Vandenbroucke RE, Libert C. Nanobodies as therapeutics: big opportunities for small antibodies. Drug Discov Today. 2016;21:1076–113.

Article  CAS  PubMed  Google Scholar 

Fan J, Zhuang X, Yang X, Xu Y, Zhou Z, Pan L, et al. A multivalent biparatopic EGFR-targeting nanobody drug conjugate displays potent anticancer activity in solid tumor models. Signal Transduct Target Ther. 2021;6:320.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Xian Z, Ma L, Zhu M, Li G, Gai J, Chang Q, et al. Blocking the PD-1-PD-L1 axis by a novel PD-1 specific nanobody expressed in yeast as a potential therapeutic for immunotherapy. Biochem Biophys Res Commun. 2019;519:267–73.

Article  CAS  PubMed  Google Scholar 

Kontermann RE. Strategies for extended serum half-life of protein therapeutics. Curr Opin Biotechnol. 2011;22:868–76.

Article  CAS  PubMed  Google Scholar 

Vincke C, Loris R, Saerens D, Martinez-Rodriguez S, Muyldermans S, Conrath K. General Strategy to Humanize a Camelid single-domain antibody and identification of a Universal Humanized Nanobody Scaffold. J Biol Chem. 2009;284:3273–84.

Article  CAS  PubMed